Commentary on Pharmacologically Meaningful Half-Life.

IF 2.4 4区 医学 Q3 PHARMACOLOGY & PHARMACY Journal of clinical pharmacology Pub Date : 2022-07-01 DOI:10.1002/jcph.2051
Nick Holford
{"title":"Commentary on Pharmacologically Meaningful Half-Life.","authors":"Nick Holford","doi":"10.1002/jcph.2051","DOIUrl":null,"url":null,"abstract":"Chaiken and Pai have proposed that there is a need for a pharmacologically meaningful half-life in order to provide a single descriptor to account for the duration of pharmacologic effect and dosing interval.1 Although they show in their introductory remarks that they are aware of pharmacometrics and systems biology, they have also clearly illustrated the limitations of a single parameter to describe the relationship between concentration and effect. A description of the time course of drug effect, and hence the duration, requires, at a minimum, a description of the time course of concentration and the relationship between concentration and effect. The simplest pharmacokinetic model for the time course of concentration involves a bolus input, a single distribution volume (V), and a first-order elimination process, defined by clearance (CL). The simplest realistic pharmacodynamic model has a maximum effect (Emax) and the concentration at 50% of Emax (C50). Ignoring more realistic input processes and delays between plasma concentration and effect, this means that a minimum of four parameters are required (V, CL, Emax, and C50). Thus, even the simplest description that can account for the duration of pharmacologic effect requires four parameters it is logically impossible and scientifically incorrect to imagine that a single half-life parameter can be found to describe the complexity. This is illustrated in Figures 1–3, which show the dramatic change in the duration of drug effect with increasing initial concentration (equivalent to increasing dose). The pharmacokinetic and pharmacodynamic parameters rest unchanged only the dose has changed. There is no single half-life that can predict or explain these changes based on the simplest possible realistic description of drug effect. Instead of searching for the impossible by looking for a single half-life to describe complex drug effects, clinicians are advised to learn the basic principles Figure 1. Time course of concentration (blue) and effect (red) with a peak concentration equal to C50. The concentration half-life is about 7 time units. Concentrations are mainly lower than the C50, and thus the effect is approximately proportional to the concentration. The time course of the effect is similar to the time course of concentration, but does not follow the exponential decrease and therefore cannot be described with a half-life of effect.","PeriodicalId":15536,"journal":{"name":"Journal of clinical pharmacology","volume":"62 7","pages":"833-834"},"PeriodicalIF":2.4000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1c/bb/JCPH-62-833.PMC10138753.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/jcph.2051","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Chaiken and Pai have proposed that there is a need for a pharmacologically meaningful half-life in order to provide a single descriptor to account for the duration of pharmacologic effect and dosing interval.1 Although they show in their introductory remarks that they are aware of pharmacometrics and systems biology, they have also clearly illustrated the limitations of a single parameter to describe the relationship between concentration and effect. A description of the time course of drug effect, and hence the duration, requires, at a minimum, a description of the time course of concentration and the relationship between concentration and effect. The simplest pharmacokinetic model for the time course of concentration involves a bolus input, a single distribution volume (V), and a first-order elimination process, defined by clearance (CL). The simplest realistic pharmacodynamic model has a maximum effect (Emax) and the concentration at 50% of Emax (C50). Ignoring more realistic input processes and delays between plasma concentration and effect, this means that a minimum of four parameters are required (V, CL, Emax, and C50). Thus, even the simplest description that can account for the duration of pharmacologic effect requires four parameters it is logically impossible and scientifically incorrect to imagine that a single half-life parameter can be found to describe the complexity. This is illustrated in Figures 1–3, which show the dramatic change in the duration of drug effect with increasing initial concentration (equivalent to increasing dose). The pharmacokinetic and pharmacodynamic parameters rest unchanged only the dose has changed. There is no single half-life that can predict or explain these changes based on the simplest possible realistic description of drug effect. Instead of searching for the impossible by looking for a single half-life to describe complex drug effects, clinicians are advised to learn the basic principles Figure 1. Time course of concentration (blue) and effect (red) with a peak concentration equal to C50. The concentration half-life is about 7 time units. Concentrations are mainly lower than the C50, and thus the effect is approximately proportional to the concentration. The time course of the effect is similar to the time course of concentration, but does not follow the exponential decrease and therefore cannot be described with a half-life of effect.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
药理学意义半衰期评论。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.10
自引率
3.40%
发文量
176
审稿时长
2 months
期刊介绍: The Journal of Clinical Pharmacology (JCP) is a Human Pharmacology journal designed to provide physicians, pharmacists, research scientists, regulatory scientists, drug developers and academic colleagues a forum to present research in all aspects of Clinical Pharmacology. This includes original research in pharmacokinetics, pharmacogenetics/pharmacogenomics, pharmacometrics, physiologic based pharmacokinetic modeling, drug interactions, therapeutic drug monitoring, regulatory sciences (including unique methods of data analysis), special population studies, drug development, pharmacovigilance, womens’ health, pediatric pharmacology, and pharmacodynamics. Additionally, JCP publishes review articles, commentaries and educational manuscripts. The Journal also serves as an instrument to disseminate Public Policy statements from the American College of Clinical Pharmacology.
期刊最新文献
Natural History and Real-World Data in Rare Diseases: Applications, Limitations, and Future Perspectives. Overview of Clinical Pharmacology Packages of New Drug Applications Approved for the Treatment of Rare Diseases. Regulatory Framework for Drug Development in Rare Diseases. Bridging the Gap With Clinical Pharmacology in Innovative Rare Disease Treatment Modalities: Targeting DNA to RNA to Protein. Think Rare, Think Inside and Out: Simple Question-Based Approach to Complex Rare Disease Drug Development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1